Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review
The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Ketamine and its enantiomer S-ketamine (esketamine) are promising candidates to produce a rapid-onset antidepressant effect in treatment-resistant depression. Ketamine causes continued blockade of the glutamate N-methyl-D-aspartate (NMDA) receptor, though this might not primarily mediate the antidepressant effect. Alternative hypotheses include selectivity for the NMDA receptor subtype containing the NMDA receptor subunit 2B (NR2B), inhibition of the phosphorylation of the eukaryotic elongation factor 2 (eEF2) kinase, increased expression of brain-derived neurotrophic factor (BDNF) and tropomyosin receptor kinase B (TrKB), and activation of the mammalian target of rapamycin (mTOR) signaling pathway, alongside other independent actions attributed to the ketamine metabolism to R-hydroxynorketamine (R-HNK). The enantiomer S-ketamine (esketamine) displays approximately fourfold greater affinity for the glutamate NMDA receptor in vitro than R-ketamine. Proof-of-concept single-dose and repeat-dose studies with intravenous ketamine show a significant antidepressant and probably antisuicidal effect in the short term, with response rates over 60% as early as 4.5 h after a single dose, with a sustained effect after 24 h, and over 40% after 7 days. This response can be further sustained over several weeks with repeated doses (two to three doses per week). Tolerability seems acceptable in the short term, with transient elevation of blood pressure and mild and transient dissociative and p…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Longer term safety signals are still emerging, including concerns related to abuse liability, urinary symptoms, and cumulative neurocognitive effects with repeated exposure [82,86,90].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [86]
In the citing paper
“Dissociative and psychotomimetic effects are common, typically transient, and sometimes accompanied by cardiovascular changes [85,86,87].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [86]
In the citing paper
“These acute and transient effects include an increase in blood pressure (usually asymptomatic), nausea and vomiting, perceptual disturbance, drowsiness, dizziness and dissociation.43,76–78”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [76]
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Mechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127
Rush, A. J. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.11.1905 · Cited by 870
Research works printed but not linked: 1
- Short B, Fong J, Galvez V, Shelker W, Loo CK. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry [Internet]. 2017; Available from: http://linkinghub.elsevier.com/retrieve/pii/S2215036617302729 .
Cited by
Numakawa, T., Odaka, H., & Adachi, N. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113650 · Cited by 353
“Therapy-response rate reaches over 60% of monoaminergic antidepressant drug non-responders and tolerability seems acceptable at least in the short term [66].”
BackgroundMonoaminergic system and depression
Perez-Caballero, L., Torres-Sanchez, S., Romero-López-Alberca, C., González-Saiz, F., Mico, J. A., & Berrocoso, E. (2019) · Cell and Tissue Research · doi:10.1007/s00441-018-2978-8 · Cited by 204
“…interest in the glutamatergic system has recently been stimulated through the rapid and sustained antidepressant effect evoked in treatment-resistant depressed patients by ketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist (Molero et al. 2018) or its isomer, esketamine.”
BackgroundMatveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320916657 · Cited by 209
Li, C.-T., Yang, K.-C., & Lin, W.-C. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00767 · Cited by 162
Substance-Induced Psychoses: An Updated Literature Review
Fiorentini, A., Cantù, F., Crisanti, C., Cereda, G., Oldani, L., & Brambilla, P. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.694863 · Cited by 197
Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments
Kadriu, B., Musazzi, L., Henter, I. D., Graves, M., Popoli, M., & Zarate, C. A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy094 · Cited by 165
“While a full review of ketamine’s antidepressant effects is beyond the scope of this article, the interested reader is referred to several recent reviews of this subject (Abdallah et al., 2018; Molero et al., 2018).”
BackgroundEsketamine for treatment resistant depression
Swainson, J., Thomas, R. K., Archer, S., Chrenek, C., MacKay, M.-A., Baker, G., Dursun, S., Klassen, L. J., Chokka, P., & Demas, M. L. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1640604 · Cited by 151
HiPSC-derived multi-organoids-on-chip system for safety assessment of antidepressant drugs
Yin, F., Zhang, X., Wang, L., Wang, Y., Zhu, Y., Li, Z., Tao, T., Chen, W., Yu, H., & Qin, J. (2021) · Lab on a Chip · doi:10.1039/d0lc00921k · Cited by 139
Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry
Hanson, J. E., Yuan, H., Perszyk, R. E., Banke, T. G., Xing, H., Tsai, M.-C., Menniti, F. S., & Traynelis, S. F. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01614-3 · Cited by 113
Positive affect and reward processing in the treatment of depression, anxiety and trauma
Craske, M. G., Dunn, B. D., Meuret, A. E., Rizvi, S. J., & Taylor, C. T. (2024) · Nature Reviews Psychology · doi:10.1038/s44159-024-00355-4 · Cited by 124
“Along with the mechanisms of action, the durability of effects, high abuse potential and cost remain critical concerns for the use of ketamine 254,272,273 .”
Gáll, Z., Farkas, S., Albert, Á., Ferencz, E., Vancea, S., Urkon, M., & Kolcsár, M. (2020) · Biomolecules · doi:10.3390/biom10050801 · Cited by 102
“Recently, ketamine and its enantiomer S-ketamine have been rediscovered as rapid acting antidepressants with demonstrated efficiency in treatment-resistant depression [18,19].”
BackgroundPrevention of suicidal behavior in bipolar disorder
Tondo, L., Vázquez, G. H., & Baldessarini, R. J. (2020) · Bipolar Disorders · doi:10.1111/bdi.13017 · Cited by 105
“Juveniles with BD 6550 [6040-7100] 124 [57-236] 52.”
Song, N., Yang, Y., Zheng, Z., Shi, W.-C., Tan, A.-P., Shan, X.-S., Liu, H., Meng, L., Peng, K., & Ji, F. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.47886 · Cited by 104
Zhang, Y., Cui, F., Ma, J., & Wang, D. (2023) · British Journal of Anaesthesia · doi:10.1016/j.bja.2023.05.001 · Cited by 90
Chen, Y., Guo, Y., Wu, H., Tang, Y.-J., Sooranna, S. R., Zhang, L., Chen, T., Xie, X., Qiu, L., & Wu, X. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.0953 · Cited by 91
Fava, M., Stahl, S., Pani, L., De Martin, S., Pappagallo, M., Guidetti, C., Alimonti, A., Bettini, E., Mangano, R. M., Wessel, T., et al. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21020197 · Cited by 83
Duan, W., Cao, D., Wang, S., & Cheng, J. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00375 · Cited by 85
Gut-brain axis: A matter of concern in neuropsychiatric disorders…!
Naveed, M., Zhou, Q.-G., Chu, X., Taleb, A., Meng, F. J., Ahmed, B., Zhang, Y., Fukunaga, K., & Han, F. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110051 · Cited by 103
Wang, S., Deng, C.-M., Zeng, Y., Chen, X., Li, A.-Y., Feng, S., Xu, L., Chen, L., Yuan, H., Hu, H., et al. (2024) · BMJ · doi:10.1136/bmj-2023-078218 · Cited by 99
Witkin, J. M., Martin, A. E., Golani, L. K., Xu, N. Z., & Smith, J. L. (2019) · Advances in Pharmacology · doi:10.1016/bs.apha.2019.03.002 · Cited by 72
Medeiros, G. C., Gould, T. D., Prueitt, W. L., Nanavati, J., Grunebaum, M. F., Farber, N. B., Singh, B., Selvaraj, S., Machado-Vieira, R., Achtyes, E. D., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01652-1 · Cited by 75
Xu, L., Wang, C., Deng, C.-M., Dai, S., Zhou, Q. Y., Peng, Y., Shou, H., Han, Y., Yu, J., Liu, C.-H., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.9321 · Cited by 71
RetractedZeifman, R. J., & Wagner, A. C. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.001 · Cited by 67
Wang, W., Xu, H., Ling, B., Chen, Q., Lv, J., & Yu, W. (2022) · Medicine · doi:10.1097/md.0000000000032010 · Cited by 76
“5 to 2 times of ketamine.[7] Compared with opioids, esketamine has no significant effect of respiratory inhibitory, so it is used in pediatric anesthesia, obstetric anesthesia and auxiliary analgesia.”
BackgroundLi, X., Xiang, P., Liang, J., Deng, Y., & Du, J. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s356284 · Cited by 66
Guo, J., Qiu, D., Gu, H., Wang, X., Hashimoto, K., Zhang, G.-F., & Yang, J. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-01945-z · Cited by 75
“In future clinical practice, the optimal approach for achieving the best antidepressant effect of ketamine with minimal adverse effects remains a major challenge.”
BackgroundPark, L. T., Kadriu, B., Gould, T. D., Zanos, P., Greenstein, D., Evans, J. W., Yuan, P., Farmer, C. A., Oppenheimer, M., George, J. M., et al. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa025 · Cited by 63
“Esketamine nasal spray (Spravato) was recently approved by the FDA as an adjunctive therapy for treatment-resistant depression (TRD), but this agent shares all of ketamine’s aforementioned liabilities (Molero et al., 2018).”
BackgroundMillard, S. J., Weston-Green, K., & Newell, K. A. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109908 · Cited by 62
Banov, M. D., Young, J. R., Dunn, T., & Szabo, S. T. (2019) · CNS Spectrums · doi:10.1017/s1092852919001238 · Cited by 66
Wang, S.-M., Kim, N.-Y., Na, H.-R., Lim, H. K., Woo, Y. S., Pae, C.-U., & Bahk, W.-M. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.2.341 · Cited by 52
“It is an S-enantiomer of ketamine, which is known to have a higher affinity for the NMDA receptor than the R-enantiomer [13].”
BackgroundLi, S., Zhou, W., Li, P., & Lin, R. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.202 · Cited by 65
Off-label uses of drugs for depression
Skånland, S. S., & Cieślar‐Pobuda, A. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172732 · Cited by 63
Neuroinflammation and neuroprogression in depression: Effects of alternative drug treatments
Richardson, B., MacPherson, A., & Bambico, F. R. (2022) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2022.100554 · Cited by 66
Xiong, X., Shao, Y., Chen, D., Chen, B., Lan, X., & Shi, J. (2024) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000006925 · Cited by 51
Majeed, A., Xiong, J., Teopiz, K. M., Ng, J., Ho, R., Rosenblat, J. D., Phan, L., Cao, B., & McIntyre, R. S. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1898588 · Cited by 48
Psiuk, D., Nowak, E., Dycha, N., Łopuszańska, U., Kurzepa, J., & Samardakiewicz, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911450 · Cited by 54
“The dissociative symptoms and psychoactive effects of ketamine can lead to increasing recreational usage, and rapidly developing tolerance might lead to an increased dosage over time [32].”
BackgroundSaggu, S., Pless, A., Dew, E., Ware, D., Jiao, K., & Wang, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1543730 · Cited by 52
Antidepressants and nose-to-brain delivery: drivers, restraints, opportunities and challenges
Vitorino, C., Silva, S., Bicker, J., Falcão, A. C., & Fortuna, A. C. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.001 · Cited by 48
Ketamine, an Old–New Drug: Uses and Abuses
Vujović, K. S., Jotic, A. D., Medić, B., Srebro, D., Vujović, A., Žujović, J. T., Opanković, A., & Vučković, S. (2023) · Pharmaceuticals · doi:10.3390/ph17010016 · Cited by 55
“Furthermore, ketamine triggers the mammalian target of rapamycin (mTOR) pathway, resulting in the deactivation of glycogen synthase kinase 3 (GSK-3) and the inhibition of eukaryotic elongation factor 2 (eEF2) kinase phosphorylation [19–22].”
BackgroundAn Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine
Berardis, D. D., Tomasetti, C., Pompili, M., Serafini, G., Vellante, F., Fornaro, M., Valchera, A., Perna, G., Volpe, U., Martinotti, G., et al. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200131100316 · Cited by 47
Wang, W. T., Ling, B., Chen, Q., Xu, H., Lv, J., & Yu, W. (2023) · Medicine · doi:10.1097/md.0000000000033086 · Cited by 51
“Esketamine was an S-enantiomer of ketamine, with approximately twice higher affinity to the NMDA receptor.[9] Therefore, 0.”
BackgroundWitkin, J. M., Knutson, D. E., Rodriguez, G. J., & Shi, S. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666180730104707 · Cited by 44
Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder
Grassi, G., Cecchelli, C., Vignozzi, L., & Pacini, S. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s255375 · Cited by 44
Ketamine for Treatment of Mood Disorders and Suicidality: A Narrative Review of Recent Progress
Kritzer, M. D., Mischel, N., Young, J. R., Lai, C. S., Masand, P. S., Szabo, S. T., & Mathew, S. J. (2022) · Annals of Clinical Psychiatry · doi:10.12788/acp.0048 · Cited by 45
“43 Similar to some of the racemic studies with IV ketamine, there was a dose-response relationship with esketamine.”
Nie, J., Chen, W., Yu, J., Zhang, Y., & Wang, H. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02517-1 · Cited by 42
“Esketamine is the dextral enantiomer of ketamine and is about twice as potent as ketamine [18].”
BackgroundYan, D., Liu, B., Wei, X., Ou, W., Liao, M., Ji, S., Peng, Y., Liu, J., Wu, S., Wang, M., et al. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114867 · Cited by 38
Davis, M. T., DellaGiogia, N., Maruff, P., Pietrzak, R. H., & Esterlis, I. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01327-5 · Cited by 37
Nobile, B., Olié, É., Dubois, J., Guillaume, S., Gorwood, P. A. P. M., & Courtet, P. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674211025697 · Cited by 40
“, 2016) and the N-methyl-D-aspartate (NMDA) antagonists ketamine and esketamine (Molero et al., 2018).”
BackgroundPan, H., Steixner-Kumar, A. A., Seelbach, A., Deutsch, N. R., Ronnenberg, A., Tapken, D., von Ahsen, N., Mitjans, M., Worthmann, H., Trippe, R., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0672-1 · Cited by 39
Salloum, N. C., Fava, M., Hock, R. S., Freeman, M. P., Flynn, M., Hoeppner, B., Cusin, C., Iosifescu, D. V., Trivedi, M. H., Sanacora, G., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.09.017 · Cited by 34
“Since then, there have been several published randomized controlled trials (RCT) confirming the acute and robust antidepressant effect of a single infusion of ketamine (Ionescu & Papakostas, 2016, 2017; Molero et al., 2018).”
BackgroundEffects of Ketamine on Learning and Memory in the Hippocampus of Rats through ERK, CREB, and Arc
Shi, M., Ding, J., Li, L., Bai, H., Li, X., Lan, L., Fan, H., & Gao, L. (2020) · Brain Sciences · doi:10.3390/brainsci11010027 · Cited by 35
“In clinical applications, studies have shown that ketamine is also a potential and effective antidepressant [22,23].”
BackgroundRepurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success?
Carboni, E., Carta, A. R., Carboni, E., & Novelli, A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.657714 · Cited by 35
Repurposing Potential of Ketamine: Opportunities and Challenges
Gautam, C. S., Mahajan, S. S., Sharma, J., Singh, H., & Singh, J. (2020) · Indian Journal of Psychological Medicine · doi:10.4103/ijpsym.ijpsym_228_19 · Cited by 36
“Current antidepressants take around 2–3 weeks for producing a response, and remission is seen in around 70% of patients (30% of patients did not respond).([35]) Therefore, a rapid action of esketamine could be useful.”
BackgroundA New Paradigm for Achieving a Rapid Antidepressant Response
Malhi, G. S., Morris, G., Bell, E., & Hamilton, A. (2020) · Drugs · doi:10.1007/s40265-020-01303-1 · Cited by 34
Advances in novel molecular targets for antidepressants
Wang, Q., & Dwivedi, Y. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110041 · Cited by 34
“Mechanistically, acute blockade of NMDA receptors by ketamine causes an activation of AMPA receptors, which then modulates downstream signaling systems in the limbic system to mediate antidepressant effects (Molero et al., 2018; Zanos and Gould, 2018).”
BackgroundOverview of treatment-resistant depression
Li, C. (2023) · Progress in brain research · doi:10.1016/bs.pbr.2023.03.007 · Cited by 41
Esmethadone-HCl (REL-1017): a promising rapid antidepressant
Fava, M., Stahl, S. M., Martin, S. D., Mattarei, A., Bettini, E., Comai, S., Alimonti, A., Bifari, F., Pani, L., Folli, F. B., et al. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01571-4 · Cited by 32
Bettini, E., Stahl, S. M., De Martin, S., Mattarei, A., Sgrignani, J., Carignani, C., Nola, S., Locatelli, P., Pappagallo, M., Inturrisi, C. E., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15080997 · Cited by 31
“Progress in pharmacological characterization of uncompetitive NMDAR channel blockers by in vitro and in silico techniques, in light of experimental [3,5–9] and clinical results [13,21,37] with the same molecules, can improve our understanding NMDAR function in physiology and pathology.”
BackgroundParise, E. M., Parise, L. F., Sial, O. K., Cardona-Acosta, A. M., Gyles, T. M., Juarez, B., Chaudhury, D., Han, M., Nestler, E. J., & Bolaños‐Guzmán, C. A. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.05.002 · Cited by 33
Drug Repurposing for the Management of Depression: Where Do We Stand Currently?
Sadeghi, H. M., Adeli, I., Mousavi, T., Daniali, M., Nikfar, S., & Abdollahi, M. R. (2021) · Life · doi:10.3390/life11080774 · Cited by 35
“Mecamylamine Computational molecular docking [23] Depression (SA) [23], MDD (INV) [17,19,20,36,37]”
BackgroundYang, S., Wang, J., Li, X., Wang, T., Xu, Z., Xu, X. M., Zhou, X., & Chen, G. (2021) · Psychiatric Quarterly · doi:10.1007/s11126-020-09871-x · Cited by 32
“Theoretically it may offer an improved tolerability profile compared with other antidepressants [11].”
BackgroundZhang, Y., Ma, H., Bai, Y., Hou, X., Yang, Y., Wang, G., & Li, Y. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00125 · Cited by 29
Zhou, Y., Wu, F., Wang, C., Zheng, W., Lan, X., Deng, X., & Ning, Y. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.06.068 · Cited by 32
Zhang, J., Wang, F., Dang, J., Zheng, H., Ren, B., Liu, C., Zuo, R., Wang, R., Liu, T., & Wang, Z. (2023) · Pain and Therapy · doi:10.1007/s40122-023-00519-9 · Cited by 29
“In addition, esketamine also has antidepressant effects [26, 27].”
BackgroundTamama, K., & Lynch, M. J. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_260 · Cited by 31
Nakamura, T., Tomita, M., Horikawa, N., Ishibashi, M., Uematsu, K., Hiraki, T., Abe, T., & Uchimura, N. (2021) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12165 · Cited by 28
Psychedelics for the Treatment of Obsessive–Compulsive Disorder: Efficacy and Proposed Mechanisms
Collins, H. M. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae057 · Cited by 29
Current and up-and-coming pharmacotherapy for obsessive-compulsive disorder in adults
Grassi, G., & Pallanti, S. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1528230 · Cited by 29
“This response can be further sustained over several weeks with repeated doses (two to three doses per week) [18].”
BackgroundKetamine treatment for depression: qualitative study exploring patient views
Jilka, S., Odoi, C. M., Wilson, E., Meran, S., Simblett, S. K., & Wykes, T. (2021) · BJPsych Open · doi:10.1192/bjo.2020.165 · Cited by 29
Lim, G. (2021) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000998 · Cited by 34
Huang, A., Chen, Y., Wang, S., Du, H., Guan, A., Wu, H., Zhai, Q., Duan, N., Li, X., Pin, Z., et al. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175667 · Cited by 30
Rapid treatments for depression: Endocannabinoid system as a therapeutic target
Sharafi, A., Pakkhesal, S., Fakhari, A., Khajehnasiri, N., & Ahmadalipour, A. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104635 · Cited by 31
Zhang, L., Liu, N., Cao, L., Xin, Y., Zhang, D., Bai, Y., Zheng, W., Bi, X.-Y., Xing, B., & Zhang, W. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.113996 · Cited by 27
Ketamine in the Treatment of Depressive Episodes
Ritter, P. S., Findeis, H., & Bauer, M. (2019) · Pharmacopsychiatry · doi:10.1055/a-0991-0582 · Cited by 29
“Aside from its sedative and analgesic properties, ketamine can acutely cause dissociative symptoms, raised intracranial, and intraocular pressure and hypertension [5].”
BackgroundBaudot, J., Soeiro, T., Tambon, M., Navarro, N., Veyrac, G., Mezaache, S., & Micallef, J. (2021) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12745 · Cited by 26
“The mechanism of action of esketamine in depression is still debated [23].”
BackgroundEnantioselective Syntheses of ( S )-Ketamine and ( S )-Norketamine
Chen, C., & Lu, X. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b02575 · Cited by 27
Stahl, S. M., Martin, S. D., Mattarei, A., Bettini, E., Pani, L., Guidetti, C., Folli, F. B., de Somer, M., Traversa, S., Inturrisi, C. E., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012196 · Cited by 24
“This prolonged therapeutic effect supports the hypothesis that a short-lived, Cmax-dependent NMDAR phasic block causes the acute, concentration-dependent, Cmax-related, dissociative effects, while sustained antidepressant effects are determined by the blockade of tonically and pathologically open NMDARs [25] of the Gl…”
BackgroundEsketamine combined with SSRI or SNRI for treatment-resistant depression
Del Casale, A., Spirito, S., Arena, J. F., Preissner, S., Borro, M., Gentile, G., Modesti, M. N., Preissner, R., Ferracuti, S., & Simmaco, M. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0200 · Cited by 23
Cooper, T., Seigler, M. D., & Stahl, S. M. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231158891 · Cited by 23
“…be considered “psychoplastogens” that also induce rapid onset mental status changes such as dissociation by ketamine/esketamine (Krystal et al., 2019; Molero et al., 2018) and hallucinations/psychotomimetic experiences by psychedelics (Goodwin et al., 2022; Nielson and Guss, 2018; Reiff et al.,…”
BackgroundHack, L. M., Zhang, X., Heifets, B. D., Suppes, T. M., van Roessel, P., Yesavage, J. A., Gray, N. J., Hilton, R. A., Bertrand, C., Rodríguez, C. I., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42141-5 · Cited by 24
Transcranial magnetic stimulation and ketamine: implications for combined treatment in depression
Dębowska, W., Więdłocha, M., Dębowska, M. D., Kownacka, Z., Marcinowicz, P., & Szulc, A. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1267647 · Cited by 23
Kumari, S., Chaudhry, H. A., Sagot, A. J., Doumas, S. J., Abdullah, H. M., Alcera, E. C., Solhkhah, R., & Afzal, S. (2024) · Cureus · doi:10.7759/cureus.53987 · Cited by 28
“ESK, the (S)+enantiomer of ketamine, demonstrates a 2-4 times higher affinity for NMDA receptors than its isomer R(-) ketamine [7,8].”
BackgroundInfluentialGuanosine fast onset antidepressant-like effects in the olfactory bulbectomy mice model
Almeida, R. F., Pocharski, C. B., Rodrigues, A. L. S., Elisabetsky, E., & Souza, D. O. (2020) · Scientific Reports · doi:10.1038/s41598-020-65300-w · Cited by 25
Sartim, A. G., Marques, J., Silveira, K. M., Gobira, P. H., Guimarães, F. S., Wegener, G., & Joca, S. R. L. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108679 · Cited by 27
“Previous evidence has demonstrated that CBD attenuates the psychotomimetic effects induced by ketamine and amphetamine in mice (Moreira and Guimaraes, 2005).”
Depression in Ultra-endurance Athletes, A Review and Recommendations
Onate, J. (2018) · Sports Medicine and Arthroscopy Review · doi:10.1097/jsa.0000000000000233 · Cited by 22
Esketamine improves propofol-induced brain injury and cognitive impairment in rats
Xu, G., Wang, Y., Chen, Z., Zhang, Y., Zhang, X., & Zhang, G. (2022) · Translational Neuroscience · doi:10.1515/tnsci-2022-0251 · Cited by 21
Li, Z., Cai, G., Fan, F., Li, W., Fan, M., Lian, J., Qiu, Y., Xu, X., Lv, X., Li, Y., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02018 · Cited by 21
Song, N., Shan, X.-S., Yang, Y., Zheng, Z., Shi, W.-C., Yang, X.-Y., Li, Y., Tan, A.-P., Liu, H., Peng, K., et al. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s365068 · Cited by 20
“Esketamine, a novel N-methyl-D-aspartate receptor antagonist, has a 2-fold higher sedative potency and a lower risk of side effects than racemic ketamine.(11,12) A recent study showed that the use of esketamine countered opioid-induced respiratory depression.”
BackgroundWang, W. T., Ling, B., Zhao, H., He, J., Xu, H., Lv, J., & Wang, Q. (2024) · BMC Anesthesiology · doi:10.1186/s12871-023-02377-6 · Cited by 22
“Esketamine is an S-Enantiisomer of ketamine and has about twice the affinity to NMDA receptor (NMDAR), which is a hot topic of antidepressant research [9].”
BackgroundInfluentialLópez‐Díaz, Á., Murillo-Izquierdo, M., & Moreno-Mellado, E. (2019) · The British Journal of Psychiatry · doi:10.1192/bjp.2019.102 · Cited by 23
Kornilov, E., Erdman, H. B., Kahana, E., Fireman, S., Zarchi, O., Israelashvili, M., Reiner, J., Glik, A., Weiss, P., Paz, R., et al. (2024) · Movement Disorders · doi:10.1002/mds.29746 · Cited by 21
“55 We did not evaluate possible long-term cognitive and mood effects, although short administration is not expected to cause long term mood effects.”
BackgroundZeng, Q.-B., Zou, D.-C., Huang, X., Shang, D., Huang, X., Yang, X.-H., Ning, Y.-P., Balbuena, L., Xiang, Y., & Zheng, W. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.09.038 · Cited by 19
Transient dose-dependent effects of ketamine in neuronal oscillatory activity in Wistar Kyoto rats
Manduca, J. D. (2021) · The Atrium (University of Guelph) · doi:10.1016/j.neuroscience.2020.05.012
Ren, L., Zhang, H., Tao, W., Chen, Y., Zou, Z., Guo, X., Shen, Q., Feng, Q., & Hu, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.896628 · Cited by 21
“However, both ketamine and esketamine had significant adverse events (Zhu et al., 2016; Molero et al., 2018; Iqbal and Mathew, 2020).”
Background(2020) · Advances in Pharmacology · doi:10.1016/bs.apha.2020.04.003 · Cited by 18
Chen, Z., Gao, Y., Gao, C. Q., Zhang, Y., Zhang, L., Zhang, H., Wu, Q., Jin, Y., Guo, N., Liu, L., et al. (2025) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2025.101567 · Cited by 19
Zang, X., Zhang, J., Hu, J., Mo, X., Zheng, T., Ji, J., Xing, J., Chen, C., & Zhou, S. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.08.123 · Cited by 19
Antidepressant efficacy and side effect burden: an updated guide for clinicians
Kutzer, T., Dick, M., Scudamore, T., Wiener, M., & Schwartz, T. L. (2020) · Drugs in Context · doi:10.7573/dic.2020-2-2 · Cited by 19
“The REMS is specific to the medication requiring (1) 60 hours infusion with monitoring by a healthcare professional every 2 hours during nonsleep periods, (2) starting treatment early in the day to allow assessment of excessive sedation, (3) pulse oximetry monitoring for hypoxemia, and (4) restriction that the patient…”
MethodSingh, K., Bhatia, R., Kumar, B., Singh, G., & Monga, V. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666211102154311 · Cited by 19
“porter and Increases The Dopamine Activity [59, 60].”
Glutamine and New Pharmacological Targets to Treat Suicidal Ideation
Jiménez-Treviño, L., González-Blanco, L., Alvarez-Vázquez, C., Rodríguez-Revuelta, J., & Sáiz, P. A. (2020) · Current topics in behavioral neurosciences · doi:10.1007/7854_2020_168 · Cited by 20
Metadata
- Authors
- Molero, P., Ramos-Quiroga, J. A., Martin-Santos, R., Calvo-Sánchez, E., Gutiérrez-Rojas, L., & Meana, J. J.
- Affiliations
- Navarre Institute of Health Research (ES)
- Universitat Autònoma de Barcelona (ES)
- Universidad de Granada (ES)
- University of the Basque Country (ES)
- Corresponding author
- Molero, P.
- Venue
- CNS Drugs
- Published
- 2018-05
- Volume
- 32
- Issue
- 5
- Pages
- 411-420
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W2800815779
- Cited by
- 280
- References
- 56
- Citations by year
- 2026: 28 · 2025: 45 · 2024: 41 · 2023: 31 · 2022: 31 · 2021: 35 · 2020: 34 · 2019: 26 · 2018: 9
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, esketamine, treatment-resistant depression, NMDA receptor, NR2B subunit, eEF2 kinase, brain-derived neurotrophic factor, mTOR signaling, intranasal administration, antidepressant tolerability, dissociative effects, antisuicidal effects, neurocognitive toxicity, substance use disorder risk, long-term safety
- MeSH terms
- Animals, Antidepressive Agents, Humans, Ketamine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.